Press Release

Clinical data of Medigene’s dendritic cell vaccines to be presented at AACR conference

Martinsried/Munich, 19 March, 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces that early clinical data of its dendritic cell (DC) vaccines will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place from April 18-22 2015 in Philadelphia, USA. The clinical data to be presented were collected in ongoing studies conducted at the Department of Cellular Therapy at the Oslo University Hospital, Norway, under the responsibility of Prof. Gunnar Kvalheim. The poster presentation titled “A new generation of dendritic cells to improve cancer therapy shows prolonged progression free survival in patients with solid tumors” shows data from patients with various types of tumour which were included in this programme.

The Oslo University Hospital has an agreement with Medigene for use of Medigene’s new generation DC vaccines for their ongoing academic clinical studies.

To view the abstract of the presentation please visit: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3682&sKey=eaee2d342-dd5a-41ba-9eb4-63990d3122b8&cKey=1ff23671-9f76-44fd-891b-50b8fbd1b6&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424

About Medigene’s DC vaccines: The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Medigene Immunotherapies (formerly Trianta Immunotherapies). Currently the DC vaccines are being evaluated in two ongoing investigator-initiated trials in clinical phases II (prostate cancer) and I/II (AML, acute myeloid leukaemia). Medigene concentrates on the further development of DC vaccines in hematological malignancies and plans to initiate a further clinical study in AML shortly.

Medigene’s dendritic cell product platform allows the design of new generation dendritic cell vaccines. Dendritic cells can take up antigens efficiently, process them and present them on their surface in a form that can induce antigen-specific T cells to proliferate and mature. This way T cells can recognize and eliminate antigen-bearing tumour cells. Dendritic cells can also induce natural killer cells (NK cells) to become active and attack tumour cells. Scientists of Medigene Immunotherapies have developed new, fast and efficient methods for preparing autologous (patient-specific) mature dendritic cells which have relevant characteristics to activate both T cells and NK cells. The dendritic cells can be loaded with various tumour antigens to treat different types of cancer and are suited for treatment of minimal residual disease or use in combination therapies.

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. Medigene Immunotherapies™ is a registered trademark of Medigene Immunotherapies GmbH. Trianta Immunotherapies™ is a registered trademark of Medigene Immunotherapies GmbH. These trademarks may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please visit: http://www.medigene.de/unsubscribe